CervoMed Inc.
Key Metrics
Market Snapshot
About
CervoMed Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. Headquartered in Rockville, Maryland, the company is advancing neflamapimod, a selective p38 alpha kinase inhibitor, as a potential therapy for dementia with Lewy bodies (DLB) and other neurological conditions. CervoMed's drug candidate targets neuroinflammation, a key factor in neurodegenerative disease progression. The company was formerly known as Cerevance and rebranded following its strategic focus on neflamapimod development.